Tegobuvir

Tegobuvir is a specific, covalent inhibitor of the HCV NS5B polymerase.

Product Specifications

CAS Number

[1000787-75-6]

Product Name Alternative

GS 333126; GS-9190

UNSPSC

12352005

Hazard Statement

H302, H315, H320, H335

Target

HCV

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/Tegobuvir.html

Purity

98.01

Solubility

DMSO : ≥ 50 mg/mL

Smiles

FC1=CC=CC=C1C2=NC3=CN(CC4=NN=C(C5=CC=C(C(F)(F)F)C=C5C(F)(F)F)C=C4)C=CC3=N2

Molecular Formula

C25H14F7N5

Molecular Weight

517.40

Precautions

H302, H315, H320, H335

References & Citations

[1]Bae AS, et al. Allele-specific real-time PCR system for detection of subpopulations of genotype 1a and 1b hepatitis C NS5B Y448H mutant viruses in clinical samples. J Clin Microbiol. 2011 Sep;49 (9) :3168-74.|[2]Hebner CM, et al. The HCV non-nucleoside inhibitor Tegobuvir utilizes a novel mechanism of action to inhibit NS5B polymerase function. PLoS One. 2012;7 (6) :e39163.|[3]Wong KA, et al. Tegobuvir (GS-9190) potency against HCV chimeric replicons derived from consensus NS5B sequences from genotypes 2b, 3a, 4a, 5a, and 6a. Virology. 2012 Jul 20;429 (1) :57-62.